CAR‑T Cell Therapy: Recent Advances for MRCP

CAR‑T Cell Therapy: Recent Advances for MRCP

1. Why CAR‑T Matters for the MRCP

• Relapsed/refractory B‑cell non‑Hodgkin lymphoma (NHL) and acute lymphoblastic leukaemia (ALL) are high‑yield exam topics.

• CAR‑T is now a standard of care and a common OSCE/short‑answer scenario.

2. Mechanism (5‑minute read)

• T‑cell collection → genetic modification → expansion → infusion.

• Chimeric antigen receptor (CAR) combines an extracellular antigen‑binding domain (usually CD19) with intracellular signalling domains (CD3ζ + costimulatory domain).

3. Recent Trial & Real‑World Data (2023‑2024)

Key takeaway: Efficacy now exceeds 70 % ORR across CD19‑targeted products.

4. Safety & Management (high‑yield OSCE)

• Cytokine Release Syndrome (CRS) – grade 1‑2 (fever, hypotension) → tocilizumab ± steroids.

• ICANS (Neurotoxicity) – confusion, seizures → high‑dose steroids, monitor EEG.

• B‑cell aplasia – prolonged hypogammaglobulinaemia → IVIG replacement.

Exam tip: Always mention tocilizumab for severe CRS and steroids for ICANS.

5. New CAR‑T Technologies (2024‑2025)

6. Regulatory Milestones (UK/EU)

• Kymriah – first EMA‑approved CD19 CAR‑T (2022).

• Breyanzi – approved for R/R DLBCL (2023).

• Yescarta – extended indication for follicular lymphoma (2024).

7. MRCP High‑Yield Points

1. Indications: Relapsed/refractory DLBCL after ≥2 lines of therapy (or primary refractory disease).

2. Key toxicities: CRS & ICANS – know grading & treatment algorithm.

3. Follow‑up: Monitor B‑cell aplasia, Ig levels, and infection risk.

4. Counseling: Discuss durability of response, cost, and logistics (apheresis centre).

8. Quick Revision Checklist

• ☐ CAR‑T mechanism & CD19 target

• ☐ ORR ~70‑80 % in DLBCL/ALL

• ☐ CRS management – tocilizumab

• ☐ ICANS – steroids, ICU monitoring

• ☐ B‑cell aplasia – IVIG

9. Recommended Resources

• Guidelines: NICE TA554 (CAR‑T for DLBCL, 2023) – concise summary.

• Reviews: Lancet Oncology CAR‑T cell therapy: 2024 update.

• MRCP Question Bank: Past paper scenarios on CD19‑targeted therapy.

• Video: Royal College of Physicians webinar “CAR‑T in Practice”.

References

1. Locke FL et al. ZUMA‑7 primary analysis. NEJM 2023;389:149‑162.

2. Maude SL et al. ELIANA trial 5‑year outcomes. JCO 2024;42:100‑108.

3. European CAR‑T Registry Report 2023. BMT 2024;55:123‑130.

4. NICE TA554: CAR‑T for diffuse large B‑cell lymphoma. 2023.

Bottom line: For MRCP, be ready to discuss CAR‑T’s mechanism, indications, response rates, and toxicity management. Recent advances (dual‑target, off‑the‑shelf products) are hot topics—mention them to impress examiners!